Adoptive cell therapy with genetically modified T cells has generated exciting outcomes in
hematologic malignancies, but its application to solid tumors has proven challenging. This …

Chimeric antigen receptor (CAR) engineering of T cells has revolutionized the field of
cellular therapy for the treatment of cancer. Despite this success, autologous CAR-T cells …

Chimeric antigen receptor (CAR) T-cell therapy is the most active field in immuno-oncology
and brings substantial benefit to patients with B cell malignancies. However, the complex …

Autologous, patient-specific chimeric antigen receptor T-cell (CART) therapy has emerged
as a powerful and potentially curative therapy for cancer, especially for CD19-positive …

T-cell-based immunotherapy, such as CAR-T cells and bispecific T-cell engagers (BiTEs),
has shown promising clinical outcomes in many cancers; however, these therapies have …

Adoptive cell therapy (ACT) has achieved landmark advances in treating cancer in clinic.
Recent advances in ACT of macrophages engineered to express chimeric antigen receptors …

When optimizing chimeric antigen receptor (CAR) therapy in terms of efficacy, safety, and
broadening its application to new malignancies, there are two main clusters of topics to be …

Cell-based immunotherapies have become an exciting avenue for cancer treatment,
particularly CAR T cells, which have shown great success in treating hematological …

The redirection of T cell activity towards cancer cells via targeting of tumor-associated
antigens (TAAs) by soluble bispecific antibodies (bsAbs) or membrane-anchored chimeric …

Cell-based therapies are a rapidly developing area of regenerative medicine as dynamic
treatments that execute therapeutic functions multimodally. Monocytes and macrophages, as …